Although the selective antagonists of ETA are a worthy pursuit for DN therapy, in a DN model of mice with podocyte-specific double knockout of ETA and ETB, less albuminuria, glomerulosclerosis, and podocyte loss were observed [90]. The gene discussed is EDNRA; the disease is glomerulosclerosis.